SIMON ALEXANDER MALLAL

Summary

Affiliation: Murdoch University
Country: Australia

Publications

  1. pmc Unique features of HLA-mediated HIV evolution in a Mexican cohort: a comparative study
    Santiago Avila-Ríos
    Center for Research in Infectious Diseases, National Institute of Respiratory Diseases, Mexico City, Mexico
    Retrovirology 6:72. 2009
  2. doi request reprint HLA-B*5701 screening for hypersensitivity to abacavir
    Simon Mallal
    Royal Perth Hospital and Murdoch University, Perth, Australia
    N Engl J Med 358:568-79. 2008
  3. ncbi request reprint Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study
    A Rauch
    Centre for Clinical Immunology and Biomedical Statistics, Perth, Australia
    Clin Infect Dis 43:99-102. 2006
  4. ncbi request reprint HLA-B*5701 screening for susceptibility to abacavir hypersensitivity
    Andrew Lucas
    Centre for Clinical Immunology and Biomedical Statistics, Royal Perth Hospital and Murdoch University, Level 2, North Block, Wellington Street, Perth, WA 6000, Australia
    J Antimicrob Chemother 59:591-3. 2007
  5. doi request reprint Successful translation of pharmacogenetics into the clinic: the abacavir example
    Elizabeth Phillips
    Institute for Immunology and Infectious Diseases, Murdoch University and Department of Clinical Immunology and Immunogenetics, Royal Perth Hospital, Perth, Western Australia, Australia
    Mol Diagn Ther 13:1-9. 2009
  6. ncbi request reprint Cytokine profiling in abacavir hypersensitivity patients
    Coral Ann M Almeida
    Centre for Clinical Immunology and Biomedical Statistics, Royal Perth Hospital and Murdoch University, Perth, Australia
    Antivir Ther 13:281-8. 2008
  7. ncbi request reprint A sensitive and rapid alternative to HLA typing as a genetic screening test for abacavir hypersensitivity syndrome
    Annalise M Martin
    Centre for Clinical Immunology and Biomedical Statistics, Royal Perth Hospital and Murdoch University, Perth, Western Australia 6000, Australia
    Pharmacogenet Genomics 16:353-7. 2006
  8. ncbi request reprint Drug hypersensitivity in HIV
    Elizabeth Phillips
    Centre for Pharmacology and Infectious Diseases, Murdoch University, Murdoch, Western Australia, Australia
    Curr Opin Allergy Clin Immunol 7:324-30. 2007
  9. pmc Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant
    Annalise M Martin
    Centre for Clinical Immunology and Biomedical Statistics, Murdoch University, Second Floor, North Block, Royal Perth Hospital, Perth 6000, Australia
    Proc Natl Acad Sci U S A 101:4180-5. 2004
  10. ncbi request reprint External quality assessment of HLA-B*5701 reporting: an international multicentre survey
    Emma Hammond
    Centre for Clinical Immunology and Biomedical Statistics, Royal Perth Hospital and Murdoch University, Western Australia, Australia
    Antivir Ther 12:1027-32. 2007

Research Grants

Collaborators

Detail Information

Publications31

  1. pmc Unique features of HLA-mediated HIV evolution in a Mexican cohort: a comparative study
    Santiago Avila-Ríos
    Center for Research in Infectious Diseases, National Institute of Respiratory Diseases, Mexico City, Mexico
    Retrovirology 6:72. 2009
    ..However, it is not known whether characteristic HLA frequency distributions in different populations have resulted in additional unique footprints...
  2. doi request reprint HLA-B*5701 screening for hypersensitivity to abacavir
    Simon Mallal
    Royal Perth Hospital and Murdoch University, Perth, Australia
    N Engl J Med 358:568-79. 2008
    ..This study was designed to establish the effectiveness of prospective HLA-B*5701 screening to prevent the hypersensitivity reaction to abacavir...
  3. ncbi request reprint Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study
    A Rauch
    Centre for Clinical Immunology and Biomedical Statistics, Perth, Australia
    Clin Infect Dis 43:99-102. 2006
    ..7% of whom were positive for HLA-B*5701), we confirm the usefulness of genetic risk stratification, with no cases of abacavir hypersensitivity among 148 HLA-B*5701-negative recipients...
  4. ncbi request reprint HLA-B*5701 screening for susceptibility to abacavir hypersensitivity
    Andrew Lucas
    Centre for Clinical Immunology and Biomedical Statistics, Royal Perth Hospital and Murdoch University, Level 2, North Block, Wellington Street, Perth, WA 6000, Australia
    J Antimicrob Chemother 59:591-3. 2007
    ..It also presents the screening's impact on clinical practice and discusses the practical considerations that influence the introduction and cost-effectiveness of such screening...
  5. doi request reprint Successful translation of pharmacogenetics into the clinic: the abacavir example
    Elizabeth Phillips
    Institute for Immunology and Infectious Diseases, Murdoch University and Department of Clinical Immunology and Immunogenetics, Royal Perth Hospital, Perth, Western Australia, Australia
    Mol Diagn Ther 13:1-9. 2009
    ..The abacavir 'example' can be applied to other drugs to facilitate the development and operationalization of genetic tests that may be useful to predict and prevent otherwise unpredictable drug reactions...
  6. ncbi request reprint Cytokine profiling in abacavir hypersensitivity patients
    Coral Ann M Almeida
    Centre for Clinical Immunology and Biomedical Statistics, Royal Perth Hospital and Murdoch University, Perth, Australia
    Antivir Ther 13:281-8. 2008
    ..We have analysed the cytokine profile in antigen-presenting cells and the T-lymphocytes that are involved in the pathological immune response to abacavir...
  7. ncbi request reprint A sensitive and rapid alternative to HLA typing as a genetic screening test for abacavir hypersensitivity syndrome
    Annalise M Martin
    Centre for Clinical Immunology and Biomedical Statistics, Royal Perth Hospital and Murdoch University, Perth, Western Australia 6000, Australia
    Pharmacogenet Genomics 16:353-7. 2006
    ..To facilitate routine screening, we have developed a rapid flow cytometry method for HLA-B57 phenotyping using commercially available B17 monoclonal antibodies...
  8. ncbi request reprint Drug hypersensitivity in HIV
    Elizabeth Phillips
    Centre for Pharmacology and Infectious Diseases, Murdoch University, Murdoch, Western Australia, Australia
    Curr Opin Allergy Clin Immunol 7:324-30. 2007
    ..This review focuses on the current knowledge of the epidemiology, pathophysiology and clinical features of drug hypersensitivity reactions of drugs used in the management of the HIV-infected patient...
  9. pmc Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant
    Annalise M Martin
    Centre for Clinical Immunology and Biomedical Statistics, Murdoch University, Second Floor, North Block, Royal Perth Hospital, Perth 6000, Australia
    Proc Natl Acad Sci U S A 101:4180-5. 2004
    ..These data indicate that the concurrence of HLA-B*5701 and Hsp70-Hom M493T alleles is necessary for the development of abacavir hypersensitivity, which is likely to be mediated by an HLA-B*5701-restricted immune response to abacavir...
  10. ncbi request reprint External quality assessment of HLA-B*5701 reporting: an international multicentre survey
    Emma Hammond
    Centre for Clinical Immunology and Biomedical Statistics, Royal Perth Hospital and Murdoch University, Western Australia, Australia
    Antivir Ther 12:1027-32. 2007
    ..We tested the proficiency of HLA-B*5701 typing among laboratories using sequence-specific primer PCR...
  11. ncbi request reprint HIV/AIDS. HIV: experiencing the pressures of modern life
    David Nolan
    Centre for Clinical Immunology and Biomedical Statistics, Royal Perth Hospital and Murdoch University, Perth, Western Australia 6000, Australia
    Science 307:1422-4. 2005
  12. ncbi request reprint Immune responses to abacavir in antigen-presenting cells from hypersensitive patients
    Annalise M Martin
    Centre for Clinical Immunology and Biomedical Statistics, Royal Perth Hospital and Murdoch University, Perth, Western Australia 6000, Australia
    AIDS 21:1233-44. 2007
    ..HLA-B*5701 and Hsp70 493T alleles have been shown to predict susceptibility to this hypersensitivity...
  13. ncbi request reprint Predicting and diagnosing abacavir and nevirapine drug hypersensitivity: from bedside to bench and back again
    Annalise Martin
    Royal Perth Hospital and Murdoch University, Centre for Clinical Immunology and Biomedical Statistics, 2nd Floor, North Block, Perth, 6000 Western Australia
    Pharmacogenomics 7:15-23. 2006
    ..This review also explores the broader implications of these findings...
  14. pmc Adaptive interactions between HLA and HIV-1: highly divergent selection imposed by HLA class I molecules with common supertype motifs
    Mina John
    Centre for Clinical Immunology and Biomedical Statistics, Institute for Immunology and Infectious Diseases, Murdoch University, Perth, Western Australia, Australia
    J Immunol 184:4368-77. 2010
    ..This suggests that the interactions between the HLA/HIV peptide complex and the TCR vary significantly within HLA supertype groups, which, in turn, influences HIV-1 evolution...
  15. ncbi request reprint Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts
    Annalise M Martin
    Centre for Clinical Immunology and Biomedical Statistics, Royal Perth Hospital and Murdoch University, Perth, Western Australia
    AIDS 19:97-9. 2005
    ..These data suggest that HLA-DRB1*0101 and the CD4 status may determine susceptibility to nevirapine hypersensitivity, consistent with a CD4 T-cell-dependent immune response to nevirapine-specific antigens...
  16. pmc Accumulation of mitochondrial DNA mutations in human immunodeficiency virus-infected patients treated with nucleoside-analogue reverse-transcriptase inhibitors
    Annalise M Martin
    Centre for Clinical Immunology and Biomedical Statistics, Murdoch University, Perth, Western Australia, Australia
    Am J Hum Genet 72:549-60. 2003
    ..These data indicate that NRTI therapy provides conditions permissive for the development of peripheral-blood mtDNA mutations in vivo...
  17. ncbi request reprint Thymidine analogue-sparing highly active antiretroviral therapy (HAART)
    David Nolan
    Centre for Clinical Immunology and Biomedical Statistics, Royal Perth Hospital and Murdoch University, Perth, Western Australia
    J HIV Ther 8:2-6. 2003
    ..The safety and efficacy of TNF and ABC are also reviewed here, although the available data provide only limited knowledge of the long-term effects of these drugs in terms of toxicity and antiviral durability...
  18. ncbi request reprint The role of nucleoside reverse transcriptase inhibitors in the fat redistribution syndrome
    David Nolan
    Centre for Clinical Immunology and Biomedical Statistics, 2nd Floor, North Block, Royal Perth Hospital, Wellington Street, Perth, 6000, Western Australia
    J HIV Ther 9:34-40. 2004
    ..Implications for clinical assessment and management are also considered, within a broader contest that incorporates treatment efficacy as well as toxicity...
  19. ncbi request reprint Associations between KIR epitope combinations expressed by HLA-B/-C haplotypes found in an HIV-1 infected study population may influence NK mediated immune responses
    Silvana Gaudieri
    Centre for Clinical Immunology and Biomedical Statistics, Murdoch University and Royal Perth Hospital, Perth, WA, Australia
    Mol Immunol 42:557-60. 2005
    ....
  20. doi request reprint Hepatitis C virus drug resistance and immune-driven adaptations: relevance to new antiviral therapy
    Silvana Gaudieri
    Centre for Clinical Immunology and Biomedical Statistics, Royal Perth Hospital and Murdoch University, Western Australia, Australia
    Hepatology 49:1069-82. 2009
    ..Furthermore, we identified areas in HCV protease and polymerase that are under both potential HLA-driven pressure and therapy selection and identified six HLA-associated polymorphisms (P <or= 0.05) at known drug resistance sites...
  21. ncbi request reprint Complications associated with NRTI therapy: update on clinical features and possible pathogenic mechanisms
    David Nolan
    Centre for Clinical Immunology and Biomedical Statistics, Royal Perth Hospital and Murdoch University, Western Australia, Australia
    Antivir Ther 9:849-63. 2004
    ..In this review, the clinical manifestations, risk factors and pathological basis for NRTI-associated toxicity syndromes are explored, with an emphasis on clinical assessment and management...
  22. doi request reprint Effects of HIV type-1 immune selection on susceptability to integrase inhibitor resistance
    Monika Tschochner
    Institute for Immunology and Infectious Diseases, Royal Perth Hospital and Murdoch University, Perth, Australia
    Antivir Ther 14:953-64. 2009
    ..We examined naturally occurring polymorphisms in HIV-1 integrase sequences from 342 antiretroviral-naive individuals from the Western Australian HIV Cohort Study and the Swiss HIV Cohort Study...
  23. ncbi request reprint Host genetics and viral infections: immunology taught by viruses, virology taught by the immune system
    David Nolan
    Centre for Clinical Immunology and Biomedical Statistics, Royal Perth Hospital and Murdoch University, Level 2, North Block, Perth, Western Australia
    Curr Opin Immunol 18:413-21. 2006
    ..These issues can be considered within an evolutionary perspective that acknowledges the crucial role of adaptive host-viral relationships in shaping both host and pathogen genetic diversity...
  24. ncbi request reprint Hyperlactatemia syndromes in people with HIV infection
    Mina John
    Centre for Clinical Immunology, North Block Level 2, Royal Perth Hospital, Wellington Street, Perth, WA 6000, Australia
    Curr Opin Infect Dis 15:23-9. 2002
    ....
  25. ncbi request reprint Antiretroviral-therapy-associated lipoatrophy: current status and future directions
    David Nolan
    Centre for Clinical Immunology and Biomedical Statistics, Royal Perth Hospital and Murdoch University, Australia
    Sex Health 2:153-63. 2005
    ....
  26. ncbi request reprint Pharmacogenetics of antiretroviral therapy: genetic variation of response and toxicity
    Annalise M Martin
    Centre for Clinical Immunology and Biomedical Statistics, Royal Perth Hospital and Murdoch University, Perth, Western Australia
    Pharmacogenomics 5:643-55. 2004
    ..g., major histocompatibility complex alleles associated with abacavir hypersensitivity). The current and potential clinical utility of pharmacogenetic testing in HIV management will also be emphasized...
  27. ncbi request reprint Mitochondrial DNA depletion and morphologic changes in adipocytes associated with nucleoside reverse transcriptase inhibitor therapy
    David Nolan
    Centre for Clinical Immunology and Biomedical Statistics, Royal Perth Hospital and Murdoch University, Western Australia, Australia
    AIDS 17:1329-38. 2003
    ..Adipose tissue morphology was also assessed...
  28. ncbi request reprint Assessment of precision and concordance of quantitative mitochondrial DNA assays: a collaborative international quality assurance study
    Emma L Hammond
    Centre for Clinical Immunology and Biomedical Statistics, 2nd Floor, North Block, Royal Perth Hospital and Murdoch University, Australia
    J Clin Virol 27:97-110. 2003
    ..A number of international research groups have developed DNA quantitation assays in order to investigate the role of mitochondrial DNA depletion in anti-retroviral therapy-induced toxicities...
  29. ncbi request reprint Tumour necrosis factor-alpha gene -238G/A promoter polymorphism associated with a more rapid onset of lipodystrophy
    David Nolan
    Centre for Clinical Immunology and Biomedical Statistics, and Department of Clinical Immunology and Biochemical Genetics, Royal Perth Hospital, Perth, Western Australia
    AIDS 17:121-3. 2003
  30. pmc Exploiting knowledge of immune selection in HIV-1 to detect HIV-specific CD8 T-cell responses
    Coral Ann M Almeida
    Centre for Clinical Immunology and Biomedical Statistics, Institute of Immunology and Infectious Diseases, Murdoch University, Perth, Western Australia, Australia
    Vaccine 28:6052-7. 2010
    ..Sites of immune selection can reveal more immunogenic epitopes in HLA-diverse populations and offer insights into the nature of HLA-epitope targeting, which could be applied in vaccine design...
  31. ncbi request reprint Adverse effects of antiretroviral therapy for HIV infection: a review of selected topics
    David Nolan
    Royal Perth Hospital and Murdoch University, Centre for Clinical Immunology and Biomedical Statistics, 2nd Floor, North Block, Wellington Street, Perth, 6000, Western Australia, Australia
    Expert Opin Drug Saf 4:201-18. 2005
    ..In this review, current and emerging drug toxicities are considered with an emphasis on lipodystrophy complications...

Research Grants5

  1. HIV-1 adaptation to HLA-restricted immune responses
    Simon Mallal; Fiscal Year: 2007
    ..The results will be used to determine how well the immune responses induced by a given vaccine would recognise diverse, variably HLA-adapted HIV-1 strains at those epitopes most critical for the prevalent HLA types of the study cohort. ..